期刊文献+

脑转移瘤的治疗 被引量:6

The treatment of brain metastases
在线阅读 下载PDF
导出
摘要 随着恶性肿瘤患者病情的发展,发生脑转移瘤的概率可达到20%-40%。因此,脑转移瘤治疗方案的优化对延长患者的生存期和改善生存质量具有重要意义。本文综述了近年来国内外手术、放疗、化疗等治疗脑转移瘤相关的临床研究,对脑转移瘤的规范化治疗进行探讨。 In patients with malignant tumors with the progression of the disease,20%-40% will occur brain metastasis.Therefore,the optimization of brain metastases,treatment options to prolong survival and improve quality of life is of great significance.This paper reviews recent domestic and international clinical research of surgery,radiotherapy,chemotherapy and other treatment of brain metastases to discuss the standardization of treatment of brain metastases.
作者 房晓萌 姜达
出处 《现代肿瘤医学》 CAS 2013年第6期1398-1400,共3页 Journal of Modern Oncology
关键词 脑转移瘤 放疗 化疗 手术 分子靶向药物 brain metastases radiation therapy chemotherapy surgery molecular targeted drugs
作者简介 房晓萌(1987一),女,河北石家庄人,在读硕士研究生,主要从事肿瘤临床化疗研究。E—mail:332429610@qq.com 【通讯作者】姜达(1962一),男,河北石家庄人,主任医师,主要从事肿瘤临床化疗研究。E—mail:jiangda139@163.com
  • 相关文献

参考文献4

二级参考文献46

  • 1许亚萍,马胜林.非小细胞肺癌脑转移治疗现状[J].中国肺癌杂志,2007,10(3):259-262. 被引量:16
  • 2AndrewsDW ScottCB SperdutoPW FlandersAE GasparLE SchellMC Werner-WasikM DemasW RyuJ BaharyJP SouhamiL RotmanM MehtaMP CurranWJJr.Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ resuIts of the RTOG 9508 randomised trial[J].中国神经肿瘤杂志,2004,2(3):192-192. 被引量:216
  • 3张莉,于世英.吉非替尼单药治疗晚期非小细胞肺癌[J].中华肿瘤杂志,2006,28(7):539-541. 被引量:37
  • 4Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin, 2005, 55:74-108.
  • 5Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353 : 123-132.
  • 6Bezjak A, Tu D, Seynour L, et al. Symptom improvement in lung cancer patients treated with erlotinib : quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol, 2006, 24:3831-3837.
  • 7Groen H, Arrieta OG, Riska H, et al. The global TRUST study of erlotinib in advanced non-small-cell lung cancer(NSCLC). J Clin Oncol, 2008, 26 :abstr19000.
  • 8Mok TS, Zhou C, Kim S, et al. Efficacy and safety of erlotinib in > 1200 East/South-East(E/SE) Asian patients(pts) with advanced non-small-cell lung cancer(NSCLC). J Clin Oncol, 2008, 26: abstr 19001.
  • 9Clark GM, Zborowski DM, Santabatrbara P, et al. Smoking history and epideramal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. Clin Lung Cancer, 2006, 7:389-394.
  • 10Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oneol, 2008, 91:406-412.

共引文献148

同被引文献36

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部